{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:23:35Z","timestamp":1783981415995,"version":"3.55.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> In chronic inflammatory demyelinating polyneuropathy (CIDP), there is an urgent need for biomarkers to monitor ongoing disease activity. Serum calprotectin (CLP) induces signaling pathways involved in inflammatory processes and has been shown to correlate with markers of disease activity in other autoimmune disorders. Thus, we wanted to study the potential value of CLP in comparison to serum neurofilament light chain (sNfl) to monitor disease activity.<\/jats:p><jats:p><jats:bold>Materials and Methods:<\/jats:bold> Sera from 63 typical and atypical CIDP and 6 MMN patients with varying degrees of disease activity were analyzed in comparison with 40 healthy controls (HC) in a cross-sectional design. Association of CLP and sNfl levels with socio-demographics, disease duration, CIDP disease activity scale (CDAS), and impairment status [medical research council-sum score (MRC-SS), the inflammatory neuropathy cause and treatment disability score (INCAT-DS), grip strength, and maximum walking distance], patient-reported outcome (PRO) parameters [SF-36 questionnaire, Beck's depression index (BDI), and fatigue severity scale (FSS)], as well as treatment regime were investigated using uni- and multivariate analysis.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> CLP and sNfl levels were significantly higher in all CIDP patients compared to HC (<jats:italic>p<\/jats:italic> = 0.0009). Multivariate analysis adjusted for age and gender revealed that CLP acts as an independent predictor for CIDP and MMN. CLP was significantly associated with active disease course according to CDAS and correlated with MRC-SS, whereas sNfl correlated with parameters of disease impairment. There was no correlation with PRO, except for sNfl and the mental health composite score. Subgroup analysis revealed no differences between typical CIDP and atypical variants.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> CLP was elevated in CIDP and variants and was associated with active disease course, whereas sNfl shows further potential as biomarker of axonal degeneration. Thus, CLP might be a suitable additive biomarker for measurement of ongoing inflammation, which is greatly needed to guide better patient care in CIDP.<\/jats:p>","DOI":"10.3389\/fneur.2021.723009","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T04:18:59Z","timestamp":1631506739000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants\u2014A Potential Novel Biomarker of Disease Activity"],"prefix":"10.3389","volume":"12","author":[{"given":"Frauke","family":"Stascheit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Klose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Klehmet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrneurol.2014.117","article-title":"Diagnosis and treatment of chronic acquired demyelinating polyneuropathies","volume":"10","author":"Latov","year":"2014","journal-title":"Nat Rev Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/jnnp-2014-309697","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype","volume":"86","author":"Mathey","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B3","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1468-1331.2009.02930.x","article-title":"European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision","volume":"17","author":"Van den Bergh","year":"2010","journal-title":"Eur J Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/jnnp-2019-320314","article-title":"Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment","volume":"90","author":"Lehmann","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12883-017-0860-z","article-title":"Differences in peripheral myelin antigen-specific T cell responses and T memory subsets in atypical versus typical CIDP","volume":"17","author":"Staudt","year":"2017","journal-title":"BMC Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fneur.2018.00171","article-title":"Neurofascin and compact myelin antigen-specific T cell response pattern in chronic inflammatory demyelinating polyneuropathy subtypes","volume":"9","author":"Diederich","year":"2018","journal-title":"Front Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e639","DOI":"10.1212\/NXI.0000000000000639","article-title":"Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: clinical relevance of IgG isotype","volume":"7","author":"Cortese","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B8","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1515\/cclm-2017-0792","article-title":"Analysis of anti-ganglioside antibodies by a line immunoassay in patients with chronic-inflammatory demyelinating polyneuropathies (CIDP)","volume":"56","author":"Klehmet","year":"2018","journal-title":"Clin Chem Lab Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1111\/ene.14476","article-title":"Pathological spontaneous activity as a prognostic marker in chronic inflammatory demyelinating polyneuropathy","volume":"27","author":"Gr\u00fcter","year":"2020","journal-title":"Eur J Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/jon.12079","article-title":"Correlation of nerve ultrasound, electrophysiological and clinical findings in chronic inflammatory demyelinating polyneuropathy","volume":"25","author":"Kerasnoudis","year":"2015","journal-title":"J Neuroimaging."},{"key":"B11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1189\/jlb.1008647","article-title":"The endogenous Toll-like receptor 4 agonist S100A8\/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer","volume":"86","author":"Ehrchen","year":"2009","journal-title":"J Leukoc Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00011-018-1173-4","article-title":"Calprotectin (S100A8\/S100A9): a key protein between inflammation and cancer","volume":"67","author":"Shabani","year":"2018","journal-title":"Inflammat Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"744","DOI":"10.17235\/reed.2019.5797\/2018","article-title":"The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease","volume":"111","author":"Su\u00e1rez Ferrer","year":"2019","journal-title":"Rev Esp Enferm Dig."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1038\/ajg.2016.342","article-title":"Serum calprotectin: a novel diagnostic and prognostic marker in inflammatory bowel diseases","volume":"111","author":"Kalla","year":"2016","journal-title":"Am J Gastroenterol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3899\/jrheum.140628","article-title":"Calprotectin as a biomarker for rheumatoid arthritis: a systematic review","volume":"42","author":"Abildtrup","year":"2015","journal-title":"J Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"R69","DOI":"10.1186\/ar1939","article-title":"The S100A8\/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis","volume":"8","author":"Sunahori","year":"2006","journal-title":"Arthritis Res Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nm.2150","article-title":"The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells","volume":"16","author":"Loser","year":"2010","journal-title":"Nature medicine."},{"key":"B18","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3389\/fimmu.2015.00532","article-title":"Evidence from human and animal studies: pathological roles of CD8(+) T cells in autoimmune peripheral neuropathies","volume":"6","author":"Yang","year":"2015","journal-title":"Front Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jneuroim.2015.03.023","article-title":"Circulating lymphocyte and T memory subsets in glucocorticosteroid versus IVIG treated patients with CIDP","volume":"283","author":"Klehmet","year":"2015","journal-title":"J Neuroimmunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/jns.12319","article-title":"Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy","volume":"24","author":"van Lieverloo","year":"2019","journal-title":"J Peripher Nerv Syst."},{"key":"B22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/jns.12279","article-title":"Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies","volume":"23","author":"Mariotto","year":"2018","journal-title":"J Peripher Nerv Syst."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e02084","DOI":"10.1002\/brb3.2084","article-title":"Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy","volume":"11","author":"Hayashi","year":"2021","journal-title":"Brain Behav."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10537-2","article-title":"Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients","author":"Fukami","year":"2021","journal-title":"J Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s41467-020-14612-6","article-title":"Serum neurofilament light levels in normal aging and their association with morphologic brain changes","volume":"11","author":"Khalil","year":"2020","journal-title":"Nat Commun."},{"key":"B27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1529-8027.2010.00284.x","article-title":"Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice","volume":"15","author":"Gorson","year":"2010","journal-title":"J Peripher Nerv Syst."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/mus.880141111","article-title":"Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barr\u00e9 syndrome","volume":"14","author":"Kleyweg","year":"1991","journal-title":"Muscle Nerve."},{"key":"B29","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/mus.10045","article-title":"Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies","volume":"25","author":"Merkies","year":"2002","journal-title":"Muscle Nerve."},{"key":"B30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","article-title":"Validating the SF-36 health survey questionnaire: new outcome measure for primary care","volume":"305","author":"Brazier","year":"1992","journal-title":"BMJ."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","article-title":"The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus","volume":"46","author":"Krupp","year":"1989","journal-title":"Archiv Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0272-7358(88)90050-5","article-title":"Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation","volume":"8","author":"Beck","year":"1988","journal-title":"Clin Psychol Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1136\/jnnp-2018-318714","article-title":"Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP database","volume":"90","author":"Doneddu","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B34","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/mus.21584","article-title":"Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists","volume":"41","author":"Alshekhlee","year":"2010","journal-title":"Muscle Nerve."},{"key":"B35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ana.1088","article-title":"Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"50","author":"Hughes","year":"2001","journal-title":"Ann Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/j.1468-1331.2012.03851.x","article-title":"Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG\u2013the ICE study","volume":"20","author":"Vanhoutte","year":"2013","journal-title":"Eur J Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/00365513.2018.1550810","article-title":"Measuring calprotectin in plasma and blood with a fully automated turbidimetric assay","volume":"79","author":"\u00c5sberg","year":"2019","journal-title":"Scand J Clin Lab Investig."},{"key":"B38","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00296-018-4190-2","article-title":"Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study","volume":"39","author":"\u0160umov\u00e1","year":"2019","journal-title":"Rheumatol Int."},{"key":"B39","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat Biotechnol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin Chem Lab Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/eji.201445064","article-title":"IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis","volume":"45","author":"Schaffert","year":"2015","journal-title":"Eur J Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1529-8027.2010.00294.x","article-title":"Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"15","author":"Chi","year":"2010","journal-title":"J Peripher Nerv Syst."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13075-016-1201-0","article-title":"Calprotectin (S100A8\/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis","volume":"19","author":"Nordal","year":"2017","journal-title":"Arthritis Res Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2013-203923","article-title":"MRP8\/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis","volume":"74","author":"Choi","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s00415-017-8658-x","article-title":"Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"264","author":"Bozovic","year":"2017","journal-title":"J Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/acn3.51305","article-title":"Serum neurofilament levels and patient-reported outcomes in multiple sclerosis","volume":"8","author":"Galetta","year":"2021","journal-title":"Ann Clin Transl Neurol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e598","DOI":"10.1212\/NXI.0000000000000598","article-title":"High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS","volume":"6","author":"Thebault","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflammation."},{"key":"B48","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/ibd\/izx018","article-title":"Biomarker-based models outperform patient-reported scores in predicting endoscopic inflammatory disease activity","volume":"24","author":"Morris","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.pharmthera.2016.07.015","article-title":"S100A8\/A9: from basic science to clinical application","volume":"167","author":"Pruenster","year":"2016","journal-title":"Pharmacol Ther."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.723009\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T04:19:03Z","timestamp":1631506743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.723009\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,13]]},"references-count":49,"alternative-id":["10.3389\/fneur.2021.723009"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.723009","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,13]]},"article-number":"723009"}}